Itacitinib, placebo of itacitinib 100mg
APHP180613
Phase 2 small_molecule active
Quick answer
Itacitinib, placebo of itacitinib 100mg for Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active